HUE035164T2 - Eljárás õssejt tulajdonságokat mutató, kemoterápiás szerrel szemben rezisztens rákos sejt izolálására - Google Patents

Eljárás õssejt tulajdonságokat mutató, kemoterápiás szerrel szemben rezisztens rákos sejt izolálására Download PDF

Info

Publication number
HUE035164T2
HUE035164T2 HUE14171733A HUE14171733A HUE035164T2 HU E035164 T2 HUE035164 T2 HU E035164T2 HU E14171733 A HUE14171733 A HU E14171733A HU E14171733 A HUE14171733 A HU E14171733A HU E035164 T2 HUE035164 T2 HU E035164T2
Authority
HU
Hungary
Prior art keywords
cells
agarose
cancer
beads
cancer cells
Prior art date
Application number
HUE14171733A
Other languages
English (en)
Inventor
Lawrence Gazda
Barry Smith
Original Assignee
The Rogosin Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rogosin Inst Inc filed Critical The Rogosin Inst Inc
Publication of HUE035164T2 publication Critical patent/HUE035164T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/76—Agarose, agar-agar
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (1)

  1. Sssfesdiitó tgopyptmtok 1.» Éljmás rákfetm szenvedő egyed prepáxíatak megbatározásám, amelynek során i) egy sz említett egyedtöí vett rákos sejteket tartalmazó mintát egy agarost tartalmazó, agarózzal bevont gyöngybe kígiszttíázöftk; 0} áá említett agarözt títrtöímazé, agarózz&amp;l :bewnt gyöngyöt tenyésztjük zz említett rákos sejtek növesz·' tésebes; íií) az említett sgsrözt tartalmazó, agaróz2al bevont gyöngyöt egy kemoterápiás szerrel érimkeztöijtik; ás Ív) meghatározzuk, hogy az enilitott kemotetáptás serrel való érlntkeztotás «tán a maradók rákos sejtek közel melyik espresszáí ÖCT4-et; és vl ahol az emhtett OCV-t-et opec^y, udos ^öeh maga. ;..-wmekertéke az említett egyesi gyengébb prognózisát jelzi összeímvo«k?\a ee> char eynedaet, al-mek s,sg\ ,tmd\ne- megtelek·» kapszulázott mintájáta kévé;; OCT-t-e; expre^s-'alv <ey ián < így mrzs
HUE14171733A 2010-11-23 2011-11-22 Eljárás õssejt tulajdonságokat mutató, kemoterápiás szerrel szemben rezisztens rákos sejt izolálására HUE035164T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45839110P 2010-11-23 2010-11-23
US45839010P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
HUE035164T2 true HUE035164T2 (hu) 2018-05-02

Family

ID=46146185

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14171733A HUE035164T2 (hu) 2010-11-23 2011-11-22 Eljárás õssejt tulajdonságokat mutató, kemoterápiás szerrel szemben rezisztens rákos sejt izolálására

Country Status (20)

Country Link
US (2) US8741637B2 (hu)
EP (2) EP2777398B1 (hu)
JP (1) JP5899230B2 (hu)
KR (1) KR101874654B1 (hu)
CN (1) CN103108547B (hu)
AP (1) AP3446A (hu)
AU (1) AU2011332020B2 (hu)
BR (1) BR112013012710B1 (hu)
CA (1) CA2801370C (hu)
DK (2) DK2777398T3 (hu)
ES (2) ES2534374T3 (hu)
HK (1) HK1179827A1 (hu)
HU (1) HUE035164T2 (hu)
IL (2) IL223362A (hu)
MX (1) MX2013005836A (hu)
NZ (1) NZ603949A (hu)
PL (2) PL2777398T3 (hu)
PT (2) PT2597952E (hu)
RU (1) RU2583296C2 (hu)
WO (1) WO2012071394A1 (hu)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19511572C2 (de) * 1995-03-29 1998-02-26 Henkel Kgaa Niedrigviskose Trübungsmittelkonzentrate
US6303151B1 (en) 1996-04-03 2001-10-16 The Rogosin Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US5888497A (en) 1996-04-03 1999-03-30 The Rogosin Institute Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
US6224912B1 (en) 1996-04-03 2001-05-01 The Rogo Institute Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment
US7297331B2 (en) 1996-04-03 2007-11-20 The Rogosin Institute Beads containing restricted cancer cells producing material suppressing cancer cell proliferation
US20050053586A1 (en) * 2003-09-04 2005-03-10 Bryan Conn Entrapped stem cells and uses thereof
ATE547004T1 (de) 2005-09-26 2012-03-15 Rogosin Inst Inc Sekretionszellenhaltige macrobeads, die seakem- gold-agarose enthalten, und ihre verwendungen
US7704967B2 (en) * 2006-03-14 2010-04-27 University Of Maryland, Baltimore TFIIS and GDOWN1 as targets for cancer therapy
WO2007118242A2 (en) * 2006-04-07 2007-10-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of a constitutively resistant cancer stem cell
KR100783199B1 (ko) * 2006-05-18 2007-12-06 부산대학교 산학협력단 인간의 뇌 암 조직으로부터 확립된 신규 암 줄기 세포주ｇｂｍ 2
US20080118518A1 (en) * 2006-09-07 2008-05-22 Cirrito Thomas P Cancer stem cell-targeted cancer therapy
EP2190481B1 (en) * 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
WO2009098698A2 (en) * 2008-02-07 2009-08-13 Shahar Cohen Compartmental extract compositions for tissue engineering
US8674172B2 (en) * 2009-04-14 2014-03-18 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
WO2010124498A1 (en) * 2009-04-30 2010-11-04 Beijing Cellonis Biotechnology Co., Ltd A resistance-screened tumor stem cell, its antigen composition, an anti-tumor dendritic cell loading with said antigens, their preparation methods, uses and kits thereof as well as a dendritic cell vaccine

Also Published As

Publication number Publication date
US20130244248A1 (en) 2013-09-19
RU2012151922A (ru) 2014-12-27
JP5899230B2 (ja) 2016-04-06
BR112013012710B1 (pt) 2021-03-09
EP2777398A1 (en) 2014-09-17
AP3446A (en) 2015-10-31
KR20130132741A (ko) 2013-12-05
HK1179827A1 (zh) 2013-10-11
CN103108547A (zh) 2013-05-15
ES2534374T3 (es) 2015-04-22
WO2012071394A1 (en) 2012-05-31
EP2597952A1 (en) 2013-06-05
US9375448B2 (en) 2016-06-28
IL233227A0 (en) 2014-07-31
CN103108547B (zh) 2015-09-02
IL223362A (en) 2016-04-21
IL233227A (en) 2017-07-31
PL2597952T3 (pl) 2015-07-31
AU2011332020A1 (en) 2012-12-20
BR112013012710A2 (pt) 2016-07-12
US20140234440A1 (en) 2014-08-21
KR101874654B1 (ko) 2018-07-04
NZ603949A (en) 2014-03-28
JP2014507931A (ja) 2014-04-03
PT2597952E (pt) 2015-04-29
MX2013005836A (es) 2013-07-05
EP2777398B1 (en) 2017-04-12
PT2777398T (pt) 2017-07-21
EP2597952B1 (en) 2015-01-07
EP2597952A4 (en) 2014-01-22
ES2632066T3 (es) 2017-09-08
US8741637B2 (en) 2014-06-03
RU2583296C2 (ru) 2016-05-10
DK2777398T3 (en) 2017-06-26
AP2013006904A0 (en) 2013-06-30
CA2801370A1 (en) 2012-05-31
AU2011332020B2 (en) 2014-03-13
CA2801370C (en) 2018-03-06
DK2597952T3 (en) 2015-03-30
PL2777398T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
Morofuji et al. Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning
KR20140020863A (ko) 종양 세포 및 조직 배양
WO2011149013A1 (ja) 癌組織由来細胞塊または癌細胞凝集塊の薬剤または放射線感受性評価方法
Acheva et al. Human 3-D tissue models in radiation biology: current status and future perspectives
Pierrevelcin et al. Engineering Novel 3D Models to Recreate High‐Grade Osteosarcoma and its Immune and Extracellular Matrix Microenvironment
JP5809782B2 (ja) 癌組織由来細胞塊または癌細胞凝集塊の薬剤または放射線感受性評価方法
HUE035164T2 (hu) Eljárás õssejt tulajdonságokat mutató, kemoterápiás szerrel szemben rezisztens rákos sejt izolálására
Shirley et al. The influence of differently functionalized nanodiamonds on proliferation, apoptosis and EMT/MET phenomena in 2D and 3D tumor cell cultures
Grover et al. Blood-Brain Barrier Permeation of Glutathione-Coated Nanoparticle. SOJ Pharm PharmSci, 1 (1), 4
AU2014202491B2 (en) Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties
OA17846A (en) Method for isolating a chemotherapeutic agent resistant cancer cell with stem cell properties.
JP2019198252A (ja) 近位尿細管上皮細胞株及びその使用
Eskandari-Nasab Role of caspase-3 in supporting normal and malignant human mammary cells
Marcatti et al. STUDY ON P53 GAIN OF FUNCTION IN 3AB-OS CANCER STEM CELLS
Cramer Evaluation of Extracellular Matrix Composition and Rheology as Determinants of Growth, Invasion, and Response to Photodynamic Therapy in 3D Cell Culture Models of Pancreatic Ductal Adenocarcinoma
Fermi et al. Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition
Hülser Brain tumour development and invasion
Sendemir Development and Characterization of Cancer Stem Cell-Based Tumoroids as an Osteosarcoma Model